EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sexual Dysfunction Induced by Antidepressants—A Pharmacovigilance Study Using Data from VigiBaseTM

Rene Zeiss, Kathrin Malejko iD, Bernhard Connemann, Maximilian Gahr, Verena Durner, Heiko Graf

Pharmaceuticals · 24.06.2024 · 17 (7) · 826

DOI: 10.3390/ph17070826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 24.06.2024. Verfasst von Rene Zeiss und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sexual dysfunction is a common side effect of antidepressants, significantly impacting patients’ quality of life and treatment adherence. This study investigates the relationship between sexual dysfunction and antidepressants by analyzing data from VigiBase™, the World Health Organization’s global database of individual case safety reports. In this study, we examined, for the first time, reports related to sexual response—desire, arousal, and orgasm—by grouping appropriate side effect terms and calculated the reporting odds ratios (RORs) for various antidepressants. The findings of this study highlight a high disproportional reporting of sexual dysfunction, particularly with selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors. In contrast, agents such as agomelatine, bupropion, and mirtazapine showed a lower association. Furthermore, we investigated the correlation between reporting odds ratios and the binding affinities of antidepressants to specific neurotransmitter receptors and transporters, unveiling significant relationships that provide insights into the pharmacodynamic pathways underlying these adverse effects. For instance, a positive correlation was observed between the serotonin transporter and side effects in the category desire: r (19) = 0.67, p = 0.001 These insights underscore the necessity for clinicians to consider sexual side effects when prescribing antidepressants and to monitor and address these issues to improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

adverse drug reactionantidepressant-induced sexual dysfunctiondisproportionality analysispharmacovigilance

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy III, University of Ulm, Leimgrubenweg 12-14, 89075 Ulm, Germany.
  • Department of Psychiatry and Psychosomatic Medicine, Städtisches Klinikum Karlsruhe, Kaiserallee 10, 76133 Karlsruhe, Germany.

ORCID-Profile: Kathrin Malejko

Zitieren

APA

Zeiss, R., Malejko, K., Connemann, B., Gahr, M., Durner, V., & Graf, H. (2024). Sexual Dysfunction Induced by Antidepressants—A Pharmacovigilance Study Using Data from VigiBaseTM. Pharmaceuticals, 17(7), 826. https://doi.org/10.3390/ph17070826

Vancouver

Zeiss R, Malejko K, Connemann B, Gahr M, Durner V, Graf H. Sexual Dysfunction Induced by Antidepressants—A Pharmacovigilance Study Using Data from VigiBaseTM. Pharmaceuticals. 2024;17(7):826. doi:10.3390/ph17070826

BibTeX
@article{Zeiss2024,
  author = {Zeiss, Rene and Malejko, Kathrin and Connemann, Bernhard and Gahr, Maximilian and Durner, Verena and Graf, Heiko},
  title = {Sexual Dysfunction Induced by Antidepressants—A Pharmacovigilance Study Using Data from VigiBaseTM},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {7},
  pages = {826},
  doi = {10.3390/ph17070826}
}
Kostenlos starten →